Last reviewed · How we verify
Levemir
At a glance
| Generic name | Levemir |
|---|---|
| Also known as | Insulin Detemir |
| Sponsor | The Royal Bournemouth Hospital |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Diabetes mellitus
Common side effects
- Upper respiratory tract infection
- Headache
- Pharyngitis
- Gastroenteritis
- Influenza-like illness
- Abdominal pain
- Pyrexia
- Cough
- Viral infection
- Nausea
- Rhinitis
- Vomiting
Serious adverse events
- Hypoglycemia (severe)
- Allergic reactions
- Lipodystrophy
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Insulin Detemir in Obesity Management (NA)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes (PHASE1)
- Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER) (PHASE4)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
- The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |